MedTrace Logo

BRCA1/2 Flu Vaccine

NCT04499534 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-10-06

No results posted yet for this study

Summary

To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.

Conditions

  • BRCA1 Mutation
  • BRCA2 Mutation

Interventions

BIOLOGICAL

Seasonal influenza vaccine

To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Susan Domchek, MD · University of Pennsylvania

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04499534 on ClinicalTrials.gov